OncLive News Network

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, FACP, FASCO, detail management strategies in EGFR-mutated NSCLC.

Hope S. Rugo, MD, and Seth Wander, MD, PhD, examine how real-world evidence is increasingly informing treatment decisions in advanced ER-positive breast cancer.

Kathryn S. Nevel, MD and Michael Veronesi, MD, PhD provide an overview of the evolving imaging strategies in glioma and discuss the use of magnetic resonance imagining and amino acid PET imaging throughout the glioma patient journey.

Amer Zeidan, MBBS, reviews key updates in myelodysplastic syndromes (MDS) presented at the 2025 ASH Annual Meeting. The program highlights real-world and clinical trial data shaping care for patients with lower-risk MDS, including insights on treatment initiation and outcomes with luspatercept

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, explore research behind triplet therapies in acute myeloid leukemia.

Francine Foss, MD, and Matthew Lunning, DO, FACP, provide an in-depth review of the current and evolving treatment landscape for peripheral T-cell lymphoma (PTCL), drawing on data presented at the 2025 ASH Annual Meeting.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss ongoing research with CAR T-cell therapy in multiple myeloma and key data to emerge with this class of agents from the 2025 ASH Annual Meeting.

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss continued research and progress with CAR T-cell therapy in multiple myeloma, with updates from ASH 2025.

Lindsay Rein, MD, and Frederick Lansigan, MD, break down key data in non-advanced systemic mastocytosis from the 2025 ASH Annual Meeting.

Michael Wang, MD, and Nakhle Saba, MD, provide a comprehensive overview of the evolving treatment landscape for mantle cell lymphoma, highlighting how frontline strategies and later-line targeted therapies are reshaping clinical practice. They review emerging data on BTK and BCL2 inhibition, novel agents such as sonrotoclax, and combination approaches presented at the 2025 ASH Annual Meeting and Exposition. Wang and Saba also explore ongoing research priorities that may further refine treatment sequencing and improve long-term outcomes for patients with mantle cell lymphoma.

Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), unpack key updates in uveal melanoma, highlighting ongoing research, persisting treatment challenges, and updates from the 2025 ESMO Congress.

OncLive® will be premiering OncLive® News Network: On Location at the 2025 ASH Annual Meeting & Exposition! Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic malignancies during the conference.

This OncLive News Network series examines the expanding role of antibody drug conjugates (ADCs) in the treatment of breast cancer. Experts Paolo Tarantino, MD and Jason Aboudi Mouabbi, MD review key data from ESMO 2025 and describe how ADCs are influencing care across HER2 positive, HER2 low, hormone receptor positive, and triple negative disease. The faculty outline major findings from DESTINY Breast05, DESTINY Breast11, TROPION Breast02, and ASCENT03, emphasizing how trastuzumab deruxtecan, datopotamab deruxtecan, and sacituzumab govitecan are moving into both early and metastatic settings. The discussion highlights clinical considerations such as patient selection, biomarkers, and the influence of brain involvement or early relapse on treatment choice. The experts review safety profiles, supportive care needs, and practical issues related to infusion planning and monitoring. The series concludes with emerging strategies that include combination therapy, next generation targets, and research priorities that will shape future use of ADCs in breast cancer.

Jonathan Webster, MD, and Nikesh Shah, MD, provide a comprehensive overview of the evolving treatment landscape for acute lymphoblastic leukemia (ALL), with a focus on how frontline strategies and immunotherapy integration are reshaping patient outcomes. Across the program, they examine the role of blinatumomab in various clinical contexts, unpack how age and Philadelphia chromosome status influence therapeutic decision-making, and review emerging data for younger adults with BCR::ABL1–negative disease. Webster and Shah also highlight promising research directions and key studies to watch ahead of the 2025 ASH Annual Meeting, underscoring the rapidly advancing science driving future improvements in ALL care.

This OncLive News Network series explores the evolving role of BRAF inhibition in the management of primary central nervous system (CNS) malignancies. Experts Patrick Wen, MD and Karisa Schreck, MD, PhD review current standards of care, highlighting existing FDA-approved therapies and the clinical challenges posed by molecular diversity and treatment resistance. The discussion emphasizes how BRAF alterations—particularly V600 mutations—influence therapeutic decision-making and the incorporation of targeted inhibitors. A major focus is the emerging agent plixorafenib, a novel BRAF inhibitor designed to penetrate the CNS and target both class I and II mutations, potentially offering broader activity than existing drugs such as dabrafenib, encorafenib, vemurafenib, and tovorafenib. The faculty address safety considerations, common adverse events, and early findings from the FORTE basket trial, which is evaluating plixorafenib in recurrent or progressive BRAF-mutated CNS tumors. The series concludes with ongoing research efforts, novel molecular testing strategies, and priorities for future clinical trials.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, provide a comprehensive overview of the evolving treatment landscape for advanced gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma, highlighting current standards, unmet needs, and key clinical considerations. They review pivotal data from the EDGE-Gastric trial, discuss the design and potential impact of the phase 3 STAR-221 study, and explore where domvanalimab plus zimberelimab with chemotherapy could ultimately fit within the frontline paradigm. They also spotlight additional practice-informing findings from the 2025 ESMO Congress and outline ongoing research that may further refine therapeutic strategies in gastrointestinal oncology.

In this OncLive® NewsNetwork Presents discussion, Narjust Florez, MD, and Julia Rotow, MD, from Dana-Farber Cancer Institute, provide expert insight into the latest ESMO 2025 data on EGFR-mutated metastatic non–small cell lung cancer (mNSCLC). Through a dynamic, case-oriented dialogue, the experts review new analyses from pivotal studies—including FLAURA2, MARIPOSA, COMPEL, and PALOMA-2—that are reshaping frontline treatment and sequencing decisions. The discussion highlights evolving definitions of high-risk disease, the clinical integration of combination EGFR-targeted regimens, and innovations such as subcutaneous amivantamab delivery and ctDNA monitoring, emphasizing the translation of trial evidence into practical, patient-centered oncology care

Panelists discuss how advances in immunotherapy—particularly dostarlimab and pembrolizumab combinations—are transforming the frontline treatment landscape for advanced or recurrent endometrial cancer. Across the series, they explore evolving clinical evidence, toxicity management, guideline integration, and future research directions aimed at improving outcomes, personalizing care, and addressing ongoing unmet needs.

Panelist discuss the current state of the frontline treatment paradigm for advanced triple-negative breast cancer.

Experts discuss key WCLC updates in the diagnosis and treatment of EGFR-mutated NSCLC. The conversation highlights patient burden with frontline combination regimens and reviews pivotal data from the MARIPOSA and FLAURA2 trials.

OncLive® will be premiering OncLive® News Network: On Location at the 2025 ESMO Congress! Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across genitourinary oncology during the conference.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss updates in non–small cell lung cancer management emerging from World Conference on Lung Cancer 2025.

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the rationale for investigating IB6 as a therapeutic target in lung cancer.

OncLive® will be premiering OncLive® News Network: On Location at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer! Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss evolving treatment trends in acute lymphoblastic leukemia.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss evolving perioperative immunotherapy approaches in early-stage non–small cell lung cancer.

Experts at Ochsner MD Anderson Cancer Center review modern HAI therapy, share integration best practices, and discuss the role of the multidisciplinary care team.

Sponsored Content by Intera Oncology.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, explore emerging approaches to RAS inhibition in pancreatic ductal adenocarcinoma.

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on updates in paroxysmal nocturnal hemoglobinuria.

Bijal Shah, MD, MS, and Jae Park, MD, deliver the key data and insights for CAR T-cell therapy in acute lymphoblastic leukemia.